^
Association details:
Biomarker:PTEN deletion
Cancer:Ovarian Cancer
Drug:PF-04691502 (mTOR inhibitor, PI3K inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

Excerpt:
Mice were transplanted orthotopically with KrasG12D; Ptendel ovarian tumors and following tumor establishment was treated with vehicle (n = 5) or PF-04691502 (n = 8) at 10 mg/kg daily for 7 days...PF-04691502 inhibited tumor growth rate significantly at 2 days (1.85 ± 0.18-fold tumor growth in vehicle-treated vs. 1.07 ± 0.14-fold tumor growth in drug-treated mice; Student's t test P < 0.01) and 7 days (4.31 ± 0.63-fold tumor growth in vehicle-treated vs. 2.14 ± 0.65-fold tumor growth in drug-treated mice; Student's t test P < 0.05)...
DOI:
10.1158/1535-7163.MCT-11-0240